Seegene Inc. (KQ096530), a leading South Korean company which provides a total solution for PCR molecular diagnostics, announced an agreement with Werfen, a worldwide leader in Specialized Diagnostics, to advance discussions on the expansion of its current collaboration for the Spanish and Portuguese marketplaces through Seegene's OneSystem™ Business.

On June 9, a launching ceremony was held for the Stago Medical Device Factory. On the same day, the opening ceremony of DiaSorin’s Baoshan factory was held.

Becton, Dickinson and Company (BD) has globally introduced the new automated instrument, the BD FACSDuet Premium Sample Preparation System, for cellular diagnostic applications.

The National Institutes of Health (NIH) has awarded a $4.6 million contract to Sorrento Therapeutics to develop an in vitro diagnostic testing platform for biodefense, antimicrobial-resistant infections, and emerging infectious diseases, the firm said Tuesday.

Point-of-care testing (POCT), also known as "bedside testing" or "near-patient testing," is a test performed near or at the patient's location that may result in a change in the patient's disposition.

DiaSorin said Tuesday that it has secured CE marking for an immunodiagnostic assay to aid diagnosis of severe conditions including sepsis, septic shock, kidney diseases, and lower respiratory and urinary tract infections, and the firm is launching the assay in Europe.

Roche announced that the cobas® HPV test for use on the cobas® 6800/8800 Systems has been awarded World Health Organization (WHO) prequalification. WHO prequalification expands the availability of this critical HPV screening tool in countries that rely on the global organisation’s list in making purchasing and implementation decisions.

Looking at the overall environment, the receding of the COVID-19 testing dividend, the slowdown of conventional business growth, and the pressure from the collection policy have all brought the IVD industry into an adjustment period.

HumaDX Tech Co., Ltd. (abbreviated as "HumaDX") completed its A2 round of financing in the first quarter of this year, with this round jointly invested by Wenrun Investment and Sunland Fund.

Results from the 100,000 Genomes cohort in the U.K. show that RNA sequencing has the potential to increase the number of diagnoses given to individuals with rare disease.

Asep Medical has entered a definitive agreement with Seaspring for sepsis diagnosis technology Sepset.

MGI Tech Co., Ltd. (referred to as MGI) announced that it has entered into a comprehensive cooperation with AddLife AB, one of Europe's largest clinical testing and laboratory equipment channel providers based in Stockholm, Sweden, to accelerate the expansion of MGI's sequencing instrument and laboratory automation equipment in the Nordic region.

T2 Biosystems said on Friday that it is collaborating with Vanderbilt University Medical Center to implement and evaluate the firm's T2Bacteria Panel in clinical settings.

In the decade since Foundation Medicine first launched its FoundationOne genomic profiling test to look for specific biomarkers in tumor tissue samples, it has racked up dozens of FDA approvals allowing the test to serve as a companion diagnostic for a broad spectrum of cancer drugs.

South Korean liquid biopsy firm IMBdx said Thursday that it is expanding an ongoing collaboration with AstraZeneca under a project called PROSPER 2.0, which aims to improve access to targeted therapies for individuals with metastatic prostate cancer in markets outside the US.